Allogene Therapeutics Inc (NASDAQ: ALLO) is 5.92% higher on its value in year-to-date trading and has touched a low of $2.23 and a high of $6.89 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ALLO stock was last observed hovering at around $3.47 in the last trading session, with the day’s loss setting it -0.07%.
Currently trading at $3.40, the stock is -14.66% and -24.14% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.79 million and changing -2.02% at the moment leaves the stock -10.21% off its SMA200. ALLO registered -31.86% loss for a year compared to 6-month gain of 14.09%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -22.37% loss in the last 1 month and extending the period to 3 months gives it a 7.59%, and is -4.23% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.82% over the week and 5.76% over the month.
Profit margin for the company is -202366.25%. Distance from 52-week low is 52.47% and -50.65% from its 52-week high. The company has generated returns on investments over the last 12 months (-48.10%).
The EPS is expected to grow by 21.14% this year.
Allogene Therapeutics Inc (ALLO) Top Institutional Holders
The shares outstanding are 169.09M, and float is at 104.72M with Short Float at 29.24%.
Allogene Therapeutics Inc (ALLO) Insider Activity
The most recent transaction is an insider purchase by Parker Geoffrey M.,the company’sCHIEF FINANCIAL OFFICER. SEC filings show that Parker Geoffrey M. bought 190 shares of the company’s common stock on Jan 30 ’24 at a price of $3.60 per share for a total of $683.0. Following the purchase, the insider now owns 0.82 million shares.
Allogene Therapeutics Inc disclosed in a document filed with the SEC on Dec 18 ’23 that MESSEMER DEBORAH M. (Director) sold a total of 18,640 shares of the company’s common stock. The trade occurred on Dec 18 ’23 and was made at $2.70 per share for $50317.0. Following the transaction, the insider now directly holds 62456.0 shares of the ALLO stock.
Still, SEC filings show that on Aug 07 ’23, Mayo Stephen (Director) disposed off 10,000 shares at an average price of $4.29 for $42855.0. The insider now directly holds 25,328 shares of Allogene Therapeutics Inc (ALLO).
